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Abstract
Background/Aim—Acetaminophen (APAP)-induced Acute Liver Failure (ALF) is associated 
with significant mortality. Traditional prognostic scores lack sensitivity. Hypothesis: Serum Liver-
type Fatty Acid Binding Protein (FABP1) early (day 1) or late (day 3–5) levels are associated with 
21-day mortality in the absence of liver transplant.
Methods—Serum samples from 198 APAP-ALF patients (nested case control study with 99 
survivors, 99 non-survivors) were analyzed by ELISA methods and assessed with clinical data 
from the US Acute Liver Failure Study Group (ALFSG) Registry (1998–2014).
Results—APAP-ALF survivors had significantly lower serum FABP1 levels early (238.6 vs. 
690.8 ng/ml, p <0.0001) and late (148.4 vs. 612.3 ng/ml, p <0.0001) compared with non-survivors. 
FABP1 > 350 ng/ml was associated with significantly higher risk of death at early (p=0.0004) and 
late (p<0.0001) time points. Increased serum FABP1 early (log FABP1 odds ratio (OR) 1.31, 
p=0.027) and late (log FABP1 OR 1.50, p =0.005) were associated with significantly increased 21-
day mortality after adjusting for significant covariates (MELD, vasopressor use). Areas under the 
receiver-operating curve (AUROC) for early and late multivariable models were 0.778 and 0.907 
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respectively. AUROC of the King’s College Criteria (KCC) (Early: 0.552 alone, 0.711 with 
FABP1; Late: 0.604 alone, 0.797 with FABP1) and ALFSG prognostic index (Early: 0.686 alone, 
0.766 with FABP1; Late: 0.711 alone, 0.815 with FABP1) significantly improved with the addition 
of FABP1 (p <0.002 for all).
Conclusion—In patients with APAP-ALF, FABP1 may have good potential to discriminate 
survivors from non-survivors and may improve models currently used in clinical practice. 
Validation of FABP1 as a clinical prediction tool in APAP-ALF warrants further investigation.
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liver type fatty acid binding protein; Multiorgan failure; prognosis; ALFSG index
INTRODUCTION
Acute liver failure (ALF) is defined by the occurrence of encephalopathy and hepatic 
synthetic dysfunction within 26 weeks of the first symptoms of liver disease(1). Currently 
the most common cause of ALF in North America is acetaminophen (APAP) (2, 3). The 
most widely used prognostic criteria in APAP-ALF patients are the King’s College criteria 
(KCC) (4, 5). While initially published in 1989, subsequent studies that have utilized KCC 
have shown relatively poor sensitivity of the APAP criteria, ranging between 25–76% (3, 6–
9). More recently, the ALFSG prognostic index also demonstrated limited sensitivity (41%) 
in APAP-ALF(9).
Liver transplant (LT) in APAP-ALF presents significant challenges due to the rapidity and 
severity of illness (i.e. high risk of cerebral edema and multiorgan failure), the potential for 
recovery without LT and the presence of concomitant complex psychosocial issues 
(contraindications) in several patients (10–12). Given advances in critical care management 
of ALF, some patients may have a good outcome despite meeting KCC and potentially could 
avoid unnecessary LT in the presence of improved prognostic markers or scores (7, 13).
Fatty acid binding proteins (FABP) are small (<15 kDa) cytoplasmic proteins that are 
abundantly expressed in tissues with active fatty acid metabolism, including hepatocytes. 
The primary function of FABPs is the intracellular transport of long-chain fatty acids(14). 
The cellular expression of FABPs is responsive to changes in lipid metabolism which can be 
induced either by pathophysiological conditions, such as ischemia/inflammation(15). Liver-
type FABP (FABP1), significantly expressed in hepatocytes, enterocytes and to a lesser 
degree in renal tubular cells, has been associated with liver injury(16). Levels of FABP1 
have been found to be elevated in patients with hepatocyte injury secondary to alcohol or 
drug toxicity (17). To date there are no published investigations on the role of FABP1 as a 
biomarker in patients with ALF. FABP1 may have potential relevance in ALF given the 
severity of hepatic injury, and furthermore the potential for recovery in the absence of 
transplant, particularly in APAP-ALF.
This nested case control study of randomly selected samples from prospectively enrolled 
patients from the US Acute Liver Failure Study Group (ALFSG) registry aimed to examine 
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levels of FABP1 in APAP-ALF patients. Specifically, our primary objectives were to test the 
following hypotheses
a. Higher FABP1 serum levels are significantly associated with 21-day transplant-
free mortality (in the absence of transplant).
b. A threshold value of FABP1 is significantly associated with 21-day mortality.
c. Elevated serum levels of FABP1 in APAP-ALF are significantly associated with 
21-day mortality after adjusting for other significant covariates.
d. The addition of FABP1 improves the performance of previously described 
prognostic models in APAP-ALF (KCC, ALFSG prognostic index).
METHODS
Study Design
This study is a nested case control study of prospectively collected data and biosamples of 
198 patients enrolled in the US ALFSG registry/biorepository and is outlined in detail in 
Supplementary File 1. Between January 1998-December 2014, 1027 APAP-ALF patients 
were enrolled in the registry. Of these 704 patients were alive at day 21 in the absence of LT. 
We identified 124 survivors that had early and late serum samples for analysis of which 99 
were randomly selected for analysis. Of 224 patients who died in the absence of LT, 87 
patients had early and late samples (all were included in this analysis). A further 12 patients 
with an early sample (of a possible 92) were randomly selected for inclusion in this analysis. 
Random selection of patients was performed by personnel not involved in the analysis of the 
samples or statistical analysis for the paper. All enrolling centers were tertiary academic 
centers and all but one were liver transplant centers. The authors’ Institutional Review Board 
(IRB)/Health research ethics boards of all enrolling US ALFSG sites have approved all 
research and all clinical investigation has been conducted according to the principles 
expressed in the 1975 Declaration of Helsinki. Given patients were unable to provide written 
consent (critical illness, hepatic encephalopathy ~ HE), written assent was obtained from the 
next of kin from each patient. Each center implemented monitoring and therapeutic 
interventions according to institutional standards of care. All authors had access to the study 
data and reviewed and approved the final manuscript. Reporting of the analysis of this study 
followed the STROBE Guidelines for reporting case-control studies(18). Consistent with 
ALFSG studies (19), the primary outcome was 21-day transplant-free survival (no patients 
received transplant in this analysis).
Participants
Inclusion criteria were: 1) evidence of ALF according to the enrollment criteria for the 
ALFSG (see operational definitions) AND 2) age =18 years; and 3) HE during the first 
seven days of study admission (West Haven Criteria)(20, 21). 4) Patients within the ALFSG 
registry with primary diagnoses of APAP determined by the site investigator. Exclusion 
criteria were: 1) Cirrhosis/acute on chronic liver failure. 2) Patients without a primary 
diagnosis of APAP and 3) Patients who received a LT. Serum samples were analyzed on 
study admission (early; day 1) and late (either day 3, 4 or 5 where available). None of the 
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198 APAP-ALF patients included received a LT. Patients who received a LT were 
excluded from our study because listing for transplant is a clinical decision which is not 
standardized among ALFSG sites. A further 51 healthy controls were analyzed (University 
of Alberta) for FABP1 only.
Operational Definitions
For the purposes of this study, ALF was defined as INR ≥ 1.5 and HE within the first 26 
weeks of liver disease in a patient with an acute hepatic insult (22). HE grade was defined by 
the West Haven Criteria (simplified) as follows; grade 1 ~ any alteration in mentation, grade 
2 being somnolent or obtunded but easily rousable or presence of asterixis, grade 3 being 
rousable with difficulty and, grade 4: unresponsive to deep pain (20, 21). In this study we 
defined ‘low coma grade’ as grade 1 or 2 and ‘high coma grade’ as grade 3 or 4. The KCC 
(4) predicts poor outcome (death/transplant) if: a) pH is less than 7.3 or b) if INR is greater 
than 6.5, creatinine is greater than 3.4 mg/dL, and coma grade is high (3 or 4). The model 
for end stage liver disease (MELD) is defined as 10*(0.957*log(4)+0.378*log(bilirubin)
+1.12*log(INR)) for dialyzed patients and 10*(0.957*log(creatinine)+0.378*log(bilirubin)
+1.12*log(INR)) for patients not dialyzed (23). The ALFSG prognostic index calculates the 
log odds (logit) for 21-day transplant free survival is defined as = 2.67 - 0.95(HE*) 
+ 1.56(Etiology*) - 1.25(Vasopressor Use*) - 0.70 (ln bilirubin) - 1.35 (ln INR)(9). For low 
coma grade, HE insert 0, for high coma grade insert 1. Acetaminophen is defined by the 
ALFSG index as a favorable etiology (insert 1). For absence of vasopressor use insert 0, for 
vasopressor use insert 1.
Laboratory Assays of FABP1
FABP1 was measured in serum samples with a solid-phase enzyme-linked immunosorbent 
assay (ELISA) following manufacturer’s instructions (Biomatik, USA). Briefly, samples 
were incubated 2 hours on a monoclonal anti-FABP1 precoated plate. A specific FABP1 
biotin-conjugated polyclonal antibody solution was added for 2 hours. After washing plates, 
avidin conjugated to horseradish peroxidase was added for 30 minutes. Finally, substrate 
tetramethylbenzidine was added for 15 minutes. Reactions were stopped by addition of 
sulfuric acid and absorbance was read at 450 nm. Standard curve range from 1.56 to 200 
ng/ml. Samples were performed in duplicate and accepted valid with a variation coefficient 
less than 25%.
Clinical Variables
Clinical, biochemical and outcome data was collected prospectively as part of the U.S. 
ALFSG registry to be analyzed for the 198 patients in this study. Data assessed in this study 
from the registry included demographic (age, race, sex), comorbidities, biochemistry early 
and late (complete blood count, creatinine, transaminases, phosphate, international 
normalized ratio (INR), bilirubin, ammonia, lactate), hepatic coma grade and requirement 
for organ support (mechanical ventilation (MV), vasopressors, renal replacement therapy 
(RRT)).
Karvellas et al. Page 4














For differences between outcome groups (APAP-ALF survivors, n=99, APAP-ALF non-
survivors, n=99), categorical variables were compared using the Chi squared test or Fisher’s 
exact test (if n<10 in any cell of the two by two table). FABP1 was treated as a continuous 
variable. Continuous variables were reported as medians with interquartile range (IQR) and 
compared using the Wilcoxon rank sum test. Survival was defined as the dichotomous 
outcome, alive or dead at 21 days after enrollment into the registry (no patients received a 
LT in this analysis). A two-sided p-value of <0.05 was considered statistically significant for 
all comparisons.
In order to control for variables that may confound the effect of FABP1 on 21-day mortality, 
logistic regression analysis was performed(24). Aside from FABP1, covariates considered in 
multivariable modeling included MELD, lactate, vasopressors use, RRT, MV and high coma 
grade. Separate multivariable (logistic) regression models were derived for FABP1 early 
(day 1) and late (day 3–5) by including variables which significant on univariate analysis 
and performing backward elimination with a p-value threshold of 0.05. Model performance 
was assessed using area under the receiver operating curve (AUROC) and the Hosmer 
Lemeshow test for goodness of fit. A bootstrap approach was implemented to validate 
parameter estimates and AUROC from the multivariable regression analysis. Logistic 
regression was used to assess significance of the addition of FABP1 to existing prognostic 
scores (KCC, ALFSG prognostic Index)(9). Model performance (early and late) for KCC, 
ALFSG index, FABP1, FABP1+KCC, and FABP1+ALFSG index were assessed using 
AUROC statistics. Comparisons of AUROC statistics between models (e.g. KCC vs. FABP1 
+ KCC) were made using the Delong method(25). A threshold value of FABP1 associated 
with mortality was established based on maximizing AUROC at both early and late time 
points. SAS software version 9.3 was used for univariate comparisons and multivariable 
logistic regression modeling, and R software version 3.1.2 was used for bootstrap analysis 
and development of graphs(26).
RESULTS
Comparative Analysis of 198 APAP-ALF patients
Demographic and clinical outcomes stratified by mortality (alive at day 21, n=99; deceased, 
n=99) are shown in Table 1. No patients in this analysis received LT. Comparing APAP-ALF 
survivors and non-survivors at day 21, there were no significant differences in age (35 vs. 
40, p=0.08) or gender (female; 76% vs. 73%, p=0.63). Survivors required significantly less 
organ support during the 7-days of inpatient study (MV: 65% vs. 93%; vasopressors 12% vs. 
70%; RRT 27% vs. 45%). Survivors were less likely to achieve high (3 or 4) HE coma grade 
(62% vs. 93%, p < 0.0001) and less likely to receive mannitol for intracranial hypertension 
(22% vs. 46%, p = 0.0003). APAP-ALF survivors were less likely to have complications 
during the first 7 days of study including seizures (3% vs. 21%, p<0.0001), arrhythmias 
(25% vs. 38%, p=0.047) or gastrointestinal bleeding (8% vs. 19 %, p=0.037). On admission, 
7% of APAP-ALF survivors and 16% of non-survivors met KCC (p = 0.13).
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Amongst the 99 APAP-ALF non-survivors, the most common causes of death reported were 
multiorgan failure (52%) and neurological complications (39%). Cause of death was 
unknown in 9% of cases.
Clinical Parameters in 198 APAP-ALF Patients: Admission (Early)
Comparisons of clinical parameters on study admission are shown in Table 2. APAP-ALF 
survivors had significantly lower serum INR (2.7 vs. 3.4), bilirubin (4.1 vs. 5.0 mg/dl), 
creatinine (1.4 vs. 2.6 mg/dl) and lactate levels (2.8 vs. 7.0 mmol/L) compared to non-
survivors (p<0.003 for all comparisons). Survivors also demonstrated significantly lower 
MELD scores (23 vs. 29, p<0.0001) than non-survivors on admission. On study admission, 
survivors were significantly less likely to be on organ support (MV, 58% vs. 80%, p=0.0007; 
vasopressors, 9% vs. 42%, p<0.0001) or achieve high HE grade (57% vs. 71%, p=0.034).
Admission (early) levels of FABP1 are shown in Table 2 and graphically in Figure 1. APAP-
ALF survivors had significantly lower admission serum FABP1 levels (238.6 vs. 690.8 
ng/ml) compared with non-survivors (p<0.0001). Plots of admission FABP1 and ALT levels 
are also shown compared in Supplementary File 2.
Clinical Parameters in 186 APAP-ALF Patients: Day 3–5 (Late)
Comparisons of clinical parameters on day 3–5 (late) are shown in Table 2. Of the 99 APAP-
ALF non-survivors, 87 patients had data available at a late time point (12 died before day 3–
5). Late, APAP-ALF survivors (n=99) had significantly lower serum INR (1.5 vs. 2.5), 
bilirubin (5.5 vs. 9.8 mg/dl), creatinine (1.2 vs. 2.4 mg/dl) and lactate levels (1.7 vs. 3.8 
mmol/L) compared to non-survivors (n=87). APAP-ALF survivors also demonstrated 
significantly lower late MELD scores (14 vs. 30, p<0.0001) than non-survivors. At late time 
points, survivors were significantly less likely to be on MV (49% vs. 85%, p<0.0001) and 
vasopressors,(5% vs. 52%, p< 0.0001) or achieve high HE grade (59% vs. 88%, p<0.0001).
Late (days 3–5) levels of FABP1 are shown in Table 2 and graphically in Figure 1. APAP-
ALF survivors had significantly lower late serum FABP1 levels (148.4 vs. 612.3 ng/ml) 
compared with non-survivors (p<0.0001). FABP1 levels were significantly higher in all ALF 
patients (survivors and non-survivors) compared to healthy controls for both early and late 
time points (p<0.0001, data not shown).
Multivariable Analysis: Associations with 21-day Mortality
In order to adjust for covariates, multivariable logistic regression for 198 APAP-ALF to 
determine associations (adjusted) with 21-day mortality were performed (Table 3). Two 
models were derived; one on admission (early) and one at day 3–5 (late). Values of serum 
FABP1 were transformed to their natural logarithm (log FABP1) to comply with the 
linearity assumption in logistic regression.
Early (Admission) Model
After adjusting for covariates, the multivariable early model included requirement for 
vasopressors (odds ratio OR 3.86, 95% CI (1.65, 9.07), p=0.0019), MELD (OR 1.042 
(1.004, 1.082) per increment, p=0.03) and log FABP1 (OR 1.305 (1.031, 1.650) per unit, 
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p=0.03). This model demonstrated AUROC of 0.778. Plots of the relationship between early 
FABP1 levels and the adjusted OR of death at 21 days are shown in Supplementary File 3. 
Early models including log FABP1 adjusting for RRT and creatinine separately 
demonstrated statistical significance for FABP1 (p <0.0001 and 0.0001 respectively) but not 
for either RRT (p=0.61) nor creatinine (p=0.48) (Supplementary File 4).
Late (Day 3–5) Model
After adjusting for covariates, the multivariable late (day 3–5) model included requirement 
for vasopressors (OR 20.74(1.65, 69.07), p<0.0001), MELD (OR 1.067 ((1.021, 1.114) per 
increment, p=0.0039) and log FABP1 (OR 1.503 (1.129, 1.999) per unit, p=0.005). This 
model demonstrated AUROC of 0.907. Plots of the relationship between late FABP1 levels 
and the adjusted OR of death at 21 days are shown in Supplementary file 3. Late models 
including log FABP1 adjusting for RRT and creatinine separately demonstrated statistical 
significance for FABP1 (p <0.0001 for both) but not for either RRT (p=0.42) nor creatinine 
(p=0.54) (Supplementary file 4).
Internal Validation: Bootstrapping
To internally validate the adjusted association between FABP1 and 21-mortality, 
bootstrapping was performed to derive estimates for the early and late multivariable models 
presented in Table 3 (vasopressors, MELD, Log FABP). Validation was done using 1000 
bootstrapped samples. Performances of both early (AUROC 0.778) and late (0.906) 
bootstrapped models were consistent with original multivariable models (Supplementary file 
5).
Performance of KCC, ALFSG Index and FABP1: Early and Late
To determine the incremental benefit of FABP1 in addition to current scores in predicting 
21-day mortality, performance characteristics of KCC, the ALFSG Index (prognostic score) 
and FABP1 were calculated in early (n=198) and late (n=186). Performance was also 
assessed for composite logistic regression models (KCC + FABP1, ALFSG Index+ FABP1). 
Data is shown in Table 4.
On admission, AUROC were for KCC (0.552), ALFSG Index (0.686) and FABP1 (0.710). 
The AUROC for KCC+FABP1 was 0.711 and was significantly improved over KCC alone 
(p<0.0001). The AUROC of ALFSG Index+FABP1 was 0.766 and was significantly 
improved over ALFSG Index alone (p=0.0008).
At late time points (Day 3–5), AUROC were for KCC (0.604), ALFSG Index (0.711) and 
FABP1 (0.820). At late time points, 124 patients had complete data to calculate the ALFSG 
Index. For those 124 patients, the AUROC of FABP1 alone (n=124) was 0.757 whereas the 
AUROC ALFSG Index+FABP1 was 0.815, which was significantly improved over ALFSG 
index alone (p=0.0012). For 110 patients who had complete data to calculate the KCC, the 
AUROC of FABP1 alone (n=110) was 0.772. The AUROC for KCC+ FABP1 was 0.797 and 
was significantly improved over KCC alone (p<0.0001).
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Performance of KCC, ALFSG Index and FABP1 Threshold: Early and Late
Based on maximizing the AUROC for both early and late time points, FABP1 values greater 
than 350 ng/ml were determined to be significantly associated with mortality. Performance 
was also assessed for composite logistic regression models using this threshold (KCC + 
FABP1>350 ng/ml, ALFSG Index+ FABP1>350 ng/ml). Data is shown in Table 4.
On admission, the AUROC for KCC+FABP1>350 ng/ml was 0.651 and was significantly 
improved over KCC alone (p=0.005). The AUROC of ALFSG Index+FABP1>350 ng/ml 
was 0.720 and was not significantly improved over ALFSG Index alone (p=0.077).
At late time points, 124 patients had complete data to calculate the ALFSG Index. For those 
124 patients, the AUROC of FABP1>350 ng/ml alone (n=124) was 0.746 whereas the 
AUROC ALFSG Index+FABP1>350 ng/ml was 0.818, which was significantly improved 
over ALFSG index alone (p=0.0048). For 110 patients who had complete data to calculate 
the KCC, the AUROC of FABP1>350 ng/ml alone (n=110) was 0.760. The AUROC for 
KCC+ FABP1>350 ng/ml was 0.794 and was significantly improved over KCC alone 
(p<0.0001). Accuracy, sensitivity, and specificity and their 95% Binomial confidence 




In this nested case-control study of 198 APAP-ALF patients, we report the first published 
analysis of FABP1 in a large series of well-characterized APAP-ALF patients. Serum levels 
of FABP1 were significantly higher at early and late time points in APAP-ALF non-
survivors. After adjusting for significant covariates reflecting severity of illness (MELD, 
vasopressor dependence), serum FABP1 (log) was significantly associated with 21-day 
mortality measured at both early (admission) and late (day 3–5) time points. Finally, FABP1 
improved performance (AUROC) by using in combination with existing prognostic scores 
(KCC, ALFSG prognostic index). Serum FABP1 greater than 350 ng/ml was associated with 
significantly higher risk of death at early (p=0.0004) and late (p<0.0001) time points. We 
specifically excluded patients who received LT to avoid the inevitable difficulty of assigning 
outcome in those rescued by transplantation and because protocols for deciding whether or 
not to transplant varied between enrolling ALFSG sites.
Comparison with literature
APAP-ALF represents the severest form of hepatic injury resulting in massive necrosis. In 
the presence of hepatocyte injury, cytoplasmic proteins pass through large clefts embedded 
within a single endothelial cell layer and into the circulation. Hepatocyte damage results in 
FABP1 detection in blood (27) and has been proposed as a sensitive serum marker of 
hepatocellular damage in liver transplant recipients(28). Recently FABP1 has been shown to 
be a diagnostic marker of liver injury in patients with hepatitis C infection(29) and 
associated with drug-induced liver injury(30). However, to date FABP1 has not been 
evaluated as a prognostic marker in these conditions or ALF.
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FABP1 has physiological properties that could potentially be advantageous as a prognostic 
biomarker. It is present in high abundance in hepatocytes (approximately 2.7mg/g of liver 
tissue), has a lower molecular mass (14kDa) and shorter plasma half-life (11min) compared 
to other cytosolic proteins (e.g. ALT)(31). This suggests FABP1 as a significantly more 
sensitive biomarker of hepatocyte necrosis compared to ALT (96kDa and half-life of 40–60 
minutes); an alternate marker of hepatocyte damage but with poor prognostic value in 
APAP-ALF (see Supplementary File 2)(27). Furthermore, alpha-glutathione s-transferase 
(α-GST) has also been proposed as potential biomarker of hepatocyte damage however its 
larger size (26kDa) and relatively higher expression in kidney and intestine reduce its 
sensitivity and specificity(28).
Due to its low molecular mass, FABP1 levels in the serum are influenced by both renal 
function and RRT. FABP1 is present in significantly smaller quantities in the kidney 
(proximal tubules)(17, 32). It has been demonstrated in cirrhotic patients that elevated levels 
of urinary FABP1 (but not serum) discriminate between patients with acute tubular necrosis 
and hepatorenal syndrome (33). For this reason, it is important to adjust for renal 
dysfunction and renal support when assessing the prognostic discrimination of FABP1 in 
APAP-ALF patients. Multivariable analysis including the MELD score, which incorporates 
renal function (creatinine and presence of RRT) at both early and late time points, and was 
significantly associated with 21-day mortality. RRT was not significantly associated with 
mortality (both at early or late time points) after adjusting for covariates and therefore was 
excluded from final models due to collinearity with MELD. After adjusting for MELD, 
FABP1 was nonetheless still significantly associated with 21-day mortality at both early and 
late time points. Furthermore, elevated FABP1 levels (early and late) were significantly 
associated with 21-day mortality after adjusting for the KCC, which also incorporates renal 
function (creatinine). Hence the specificity of FABP1 for hepatic injury compared to the 
kidney and intestine may contribute to its potential discriminatory ability.
FABP1 is involved in uptake, transport and metabolism of long-chain fatty acids. In 
addition, FABP1 has multiple biologic functions including roles in fatty acid transport, 
storage and metabolism(34). FABP1 also has an important role in facilitating hepatic fatty 
acid oxidation and is involved in trafficking and delivery of various ligands to cellular 
destinations such as enzymes, membranes and nucleus(35). FABP1 also acts as a cellular 
antioxidant as it contains a cysteine group and has been found to influence cell growth, since 
it has been demonstrated to be elevated during stages of mitosis(36). Hepatic long chain 
fatty acid uptake is directly associated with FABP1 expression levels(37). Therefore, an 
increased expression of hepatocyte FABP1 could be a compensatory mechanism in attempt 
to rescue energy-deprived hepatocytes undergoing necrosis. A failed attempt elicits necrosis, 
resulting in up-regulated levels of FABP1 being released into circulation. Studies have 
demonstrated that increased hepatocyte necrosis is associated with higher mortality in 
ALF(38). Therefore we speculate massive necrosis of hepatocytes containing over-expressed 
levels of FABP1 could justify the association with non-spontaneous hepatic recovery and 
explain the higher FABP1 levels found in non-survivors.
This study demonstrated that the addition of FABP1 to both the KCC and the ALFSG 
prognostic index significantly improved discrimination between 21-day survivors and non-
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survivors when measured at both early and late time points. Use of KCC alone in this study 
yielded an AUROC of 0.552 on admission and 0.604 at later time points. This is similar to 
results published recently for the entire ALFSG cohort (AUROC 0.56 on admission)(5, 9). 
McPhail and colleagues recently demonstrated in a meta-analysis that the pooled sensitivity 
of KCC in APAP-ALF was 58%(39). Adding FABP1 to KCC significantly improved 
prognostic discrimination both at early (AUROC: KCC alone 0.552, 0.711 with FABP1) and 
late time points (0.604, 0.815 with FABP1). Similar improvements were noted when adding 
FABP1 to the ALFSG prognostic index (ALFSG Index: AUROC early alone: 0.686, 0.766 
with FABP1; late alone 0.711, 0.815 with FABP1). KCC and ALFSG prognostic scores rely 
on markers of synthetic hepatic function (INR, Bilirubin), hepatic encephalopathy (ALFSG 
Index), renal dysfunction (MELD) and organ support (vasopressors, ALFSG Index). 
Potentially FABP1 may add discriminatory and prognostic information regarding hepatic 
injury or recovery that is not captured by these other covariates.
Limitations
The following limitations of this study warrant consideration. It is a nested case control 
study and as such the event rate of the primary outcome (21-day mortality) was 50%, higher 
than published in cohort series. Although patients were enrolled and samples were collected 
prospectively, analysis was done retrospectively and therefore can comment on association 
and discrimination (between survivors and non-survivors) and not on the absolute risks of 
death according to serum FABP1 levels. To account for potential confounding in the study 
design, we performed multivariable analysis to adjust for other significant covariates 
(MELD, vasopressors, KCC, ALFSG prognostic index), which demonstrated FABP1 as a 
statistically significant discriminatory biomarker after adjusting for covariates. To avoid 
confounding related to LT since transplant listing decisions for APAP-ALF and the organ 
availability were not consistent between study centers (Simmons et al, ALFSG unpublished 
data), samples from patients who received a LT were not evaluated in this study. The case-
control design of the study may have introduced selection bias, as the primary outcome of 
survival is automatically unbalanced within the clinical profile of the groups. However in an 
attempt to reduce observation bias, data was collected prospectively and within this specific 
study design, researchers measuring FABP1 were blinded to the clinical and outcome data of 
patients at the time of patient selection and sample analysis. We did not have access to a 
control group with critical illness but not APAP-ALF as a comparator to elucidate the 
association between FABP1 and critical illness. Validation was performed with 
bootstrapping, as independent external samples were unavailable. The relationship of FABP1 
and outcomes in ALF should be validated by external samples. Nonetheless despite these 
limitations, we believe these results are robust as they include APAP-ALF cases from across 
16 tertiary liver transplant centers comprising the US ALFSG and the statistically significant 
associations between FABP1 with mortality after adjusting for significant covariates 
(MELD, vasopressors) and known prognostic scores (KCC, ALFSG Index).
Conclusions
In patients with APAP-ALF, FABP1 may have good potential to discriminate survivors from 
non-survivors and may improve models currently used in clinical practice. Validation of 
FABP1 as a clinical prediction tool in APAP-ALF warrants further investigation.
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HE hepatic encephalopathy
ICU Intensive Care Unit
INR international normalized ratio
IQR Interquartile range
KCC King’s College Criteria
LT Liver transplantation
MAP mean arterial pressure (mm Hg)
MELD model for end stage liver disease score
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“Acetaminophen-induced ALF survivors had significantly lower serum FABP1 levels 
early at serial time points compared with non-survivors after adjusting for covariates. 
FABP1 could potentially improve discrimination between survivors from non-survivors 
and may improve models currently used in clinical practice.”
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Serum levels of FABP1 (ng/ml) in healthy controls, non-survivors (early ~ admission), 
survivors (early), non-survivors (late ~ day 3–5), survivors (late).
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Table 4
Comparison of Model Performance (Early and Late) for 198 APAP-ALF patients.
Models EARLY (Day 1) LATE (Day 3–5)
Variable n AUROC (95% CI) N AUROC (95% CI)
KCC 174 0.552 (0.502,0.602) 110 0.604 (0.555,0.654)
ALFSG Index 192 0.686 (0.624,0.747) 124 0.711 (0.635,0.788)
FABP1 198 0.710 (0.639,0.782) 186 0.820 (0.760,0.881)
KCC+FABP1 174 0.711 (0.635,0.787)1 110 0.797 (0.712,0.882)3,4
ALFSG Index + FABP1 192 0.766 (0.699,0.833)2 124 0.815 (0.736,0.894)5,6
FABP1>350 ng/ml 198 0.626 (0.559,0.694) 186 0.776 (0.715,0.836)
KCC+FABP1>350 ng/ml 174 0.651 (0.577,0.726)7 110 0.794 (0.719,0.869)9,10
ALFSG Index + FABP1>350 ng/ml 192 0.720 (0.652,0.789)8 124 0.818 (0.746,0.890)11,12
ALFSG ~ Acute Liver Failure Study Group Index. AUROC ~ Area under the receiver operator curve. CI ~ Confidence intervals KCC; King’s 
College Criteria (Acetaminophen). FABP1; Liver-type Fatty acid binding protein.
Early Models (Delong method for comparison of AUROC statistics(25)):
1
FABP1+KCC vs. KCC: p < 0.0001
2
FABP1+ALFSG index vs. ALFSG index: p =0.0008
7
FABP1>350 ng/ml +KCC vs. KCC: p = 0.005
8
FABP1>350 ng/ml +ALFSG index vs. ALFSG index: p =0.077
Late Models: KCC
3
FABP1+KCC vs. KCC: p < 0.0001
4
For LATE model, only 110 patients had complete data to calculate the KCC. For those patients the AUROC of FABP1 alone (n=110) was 0.772 
(0.677, 0.866).
9
FABP1>350 ng/ml +KCC vs. KCC: p < 0.0001
10
For LATE model, only 110 patients had complete data to calculate the KCC. For those patients the AUROC of FABP1>350 alone (n=110) was 
0.760 (0.677, 0.843).
Late Models: ALFSG Index
5
FABP1+ALFSG index vs. ALFSG index: p =0.0012
6
For LATE model, only 124 patients had complete data to calculate the ALFSG Index. For those patients the AUROC of FABP1 alone (n=124) was 
0.757 (0.668, 0.845).
11
FABP1>350 ng/ml +ALFSG index vs. ALFSG index: p =0.0048
12
For LATE model, only 124 patients had complete data to calculate the ALFSG Index. For those patients the AUROC of FABP>350 ng/ml alone 
(n=124) was 0.746 (0.669, 0.823).
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